Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating brivaracetam as monotherapy in children aged 2–25 with Childhood Absence Epilepsy or Juvenile Absence Epilepsy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Childhood Absence Epilepsy
• Juvenile Absence Epilepsy

Drugs mentioned

• BRIVARACETAM (brivaracetam)

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Childhood Absence Epilepsy, Juvenile Absence Epilepsy | Phase 3 | Status: COMPLETED